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Abstract
Purpose: Radiation therapy for retroperitoneal sarcoma remains challenging because of proximity to surrounding organs at
risk (OAR). We report the use of intensity modulated radiation therapy (IMRT) in the treatment of retroperitoneal sarcomas
to minimize dose to OAR while concurrently optimizing tumor dose coverage.
Patients and methods: From January 2000 to October 2002, 10 patients (average age 56 years) with retroperitoneal sarcoma
and one with inguinal sarcoma were treated with radiation at Emory University. Prescription dose to the planning treatment
volume (PTV) was commonly 50.4 at 1.8Gy/fraction. CT simulation was used in each patient, three patients were treated
with 3D-conformal treatment (3D-CRT), and the remaining eight received multi-leaf collimator-based (MLC) IMRT.
IMRT treatment fields ranged from eight to 11 and average volume treated was 3498cc. Optimal 3D-CRT plans were
generated and compared with IMRT with respect to tumor coverage and OAR dose toxicity. Dose volume histograms were
compared for both the 3D-CRT and IMRT plans.
Results: Mean dose to small bowel decreased from 36Gy with 3D-CRT to 27Gy using IMRT, and tumor coverage (V95)
increased from 95.3% with 3D-CRT to 98.6% using IMRT. Maximum and minimum doses delivered to the PTV were
significantly increased by 6 and 22%, respectively (P¼0.011, P¼0.055). Volume of small bowel receiving >30Gy was
significantly decreased from 63.5 to 43.1% with IMRT compared with conventional treatment (P¼0.043). Seven patients
developed grade 2 nausea, three developed grade 2 diarrhea, one had grade 2 skin toxicity, and one patient developed grade
3 liver toxicity (RTOG toxicity scale). No other delayed toxicities related to radiation were observed. At a median follow-up
of 58 weeks, there were no local recurrences and only one patient developed disease progression with distant metastasis in
the liver.
Conclusions: IMRT for retroperitoneal sarcoma allowed enhanced tumor coverage and better sparing of dose to critical normal
structures such as small bowel, liver, and kidney. Escalation of dose has a positive impact on local control for retroperitoneal
sarcoma; IMRT may be an effective method to achieve this goal. We are evaluating preoperative dose escalation to 59.4Gy.
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Introduction
Intensity-modulated radiation therapy (IMRT) is a
new and revolutionary method of radiation delivery
based on the use of optimized non-uniform radiation
beam intensities incident on the patient.
1 IMRT
used in our department relies on an inverse planning
system that employs computer-assisted optimization
methods to determine the fluence intensities given to
a specific tumor volume. By setting dose constraints
to critical organs at risk (OAR) and tumor volume,
dose conformality and OAR toxicity has been opti-
mized. Local recurrence in retroperitoneal sarcoma
is the primary cause of mortality in patients with this
disease.
2–4 Retroperitoneal sarcoma has been respon-
sive to radiation dose escalation,
5–7 yet efforts to achi-
eve this with external beam radiation alone (EBRT)
have been hampered by OAR toxicity. We report the
use of IMRT as a means to minimize dose to OAR
and concurrently maximize tumor dose coverage.
The therapeutic advantage of using IMRT with
respect to toxicity profiles has been studied for a
variety of different sites. Hong et al. recently reported
the use of IMRT for whole abdomen radiation and
found bone marrow dose reduction and improved
tumor coverage when compared to traditional whole
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8 A five-field arrangement was
used and the volume of pelvic bones receiving a dose
>21Gy was reduced by 60% and tumor coverage
improved by 11.8% with the use of IMRT. Clearly,
the use of large fields, sometimes necessary for
retroperitoneal sarcoma, does not preclude employ-
ment of IMRT. The presence of small bowel in the
treatment field, as well as the close proximity of
kidney and liver, have presented a limitation to
dose escalation for tumors located in the abdomen.
We reported on the use of preoperative IMRT in
pancreatic cancer in which IMRT allowed for dose
escalation to 61.2Gy and resulted in reduced average
dose to small bowel and a 10% reduction in volume
of small bowel receiving >50Gy.
9 IMRT for head
and neck cancers has resulted in a 2–30% incidence
of late Grade 2 xerostomia in contrast to the 60–75%
incidence reported with historical controls treated
with 3D-conformal treatment (3D-CRT).
10,11 For
prostate cancer, IMRT has resulted in a signifi-
cant decrease in both acute and chronic rectal
complications.
12
Treatment of retroperitoneal sarcomas with radia-
tion has been limited due to the close proximity of
these tumors to small bowel, liver, and kidney. To
avoid critically overdosing these organs at risk (OAR),
the total dose delivered to the tumor is often
compromised and, consequently, the risk of local
recurrence is increased. Historically, these tumors
have been treated with a 3–5-cm margin around the
gross tumor volume (GTV) to include the anatomy of
the involved tissues.
5,6,13 The Radiation Therapy
Oncology Group (RTOG) in their currently open
Phase II trial evaluating multimodality treatment for
retroperitoneal sarcomas recommends a 5-cm cir-
cumferential margin, except in areas where sparing of
dose to kidneys, liver, and spinal cord are required, in
which a 3-cm margin may be allowed.
14 To treat with
tighter margins than previously described in order to
achieve dose escalation may potentially underdose
the peritoneal cavity where the risk of local recurrence
is the greatest. We believe that the use of IMRT and
intent of dose escalation does not give one a mandate
to compromise the margin that would normally be
employed in the treatment of retroperitoneal sar-
coma. The use of IMRT throughout treatment, from
the beginning, allows for optimal dose minimization
to OAR and maximization to tumor volume. Over the
past 3 years, we have consistently employed IMRT
with inverse treatment planning for the entire dura-
tion of preoperative radiation for patients with retro-
peritonealsarcoma.Grosstumorvolume,areasathigh
risk for local recurrence, and normal OAR are out-
lined on high quality CT images (2.5-mm slices) and
a three-dimensional volumetric margin is obtained
to produce a planning treatment volume (PTV).
Potential organ motion has been thought to
compromise the benefits of IMRT; recent data
indicate that the main effect of organ motion in
IMRT is an averaging of the dose distribution, which
is the same as for conventional treatment. Bortfeld
et al. calculated and statistically analyzed the
expected dose values and dose variances for volume
elements of organs that move during the delivery of
IMRT and found that the standard deviation was
within 1% of the expected value for multi-leaf
collimator (MLC) delivery.
15 To take into account
potential organ motion, we employed an additional
margin of 1cm, which is built into our PTV margin
to account for GTV movement with respiration.
We previously defined the method of 3-D outlining
areas of high risk as the volume at risk approach,
or VaRA.
9 Here, we continue to use VaRA as an
integral component of IMRT to ensure that tumor
coverage is complete and minimal allowable dose is
delivered to OAR. Although the kidneys and liver are
dose-limiting structures when treating retroperito-
neal sarcomas, the small bowel as an OAR poses the
greatest challenge. Radiation doses beyond 45–50Gy
have been associated with small bowel obstruction;
this is often the rate-limiting factor in dose escalation
to a variety of tumors in the abdominal region.
16 We
report our institutional experience with IMRT in the
treatment of retroperitoneal sarcoma. We analyzed
the benefits of IMRT with respect to the reduction of
dose to critical OAR and enhanced tumor coverage.
Dose–volume histograms of patients planned and
treated with IMRT to 50.4Gy were compared with
3D-CRT treatment plans to the same dose.
Patients and methods
Between January and October 2002, 10 patients with
retroperitoneal sarcomas and one patient with an
inguinal sarcoma were treated with radiation in the
Department of Radiation Oncology at Emory
University School of Medicine. Two of the 11
patients had surgery at outside institutions while the
remaining nine had surgery at our institution.
All outside pathological specimens were reviewed
internally. Average patient age was 56 years (range
34–82 years). Three patients presented with tumors
<10cm, seven patients had tumors between 10 and
20cm, and one patient had a tumor >20cm. Seven
patients were female and four were male. Eight of the
patients had primary tumors while the remaining
three presented with recurrence of disease. Two of
the 11 patients had pelvic involvement and nine of the
eleven patients were treated with preoperative radia-
tion followed by resection. Two patients were treated
postoperatively. All patients were evaluated preopera-
tively by computerized tomography (CT) of the chest,
abdomen, and pelvis and none had metastatic
disease. Patient variables included age at diagnosis,
sex, presentation status (primary versus recurrent),
margin status, and extent of resection (Table 1).
Tumor variables included size, location, histological
subtype, histological grade, and stage (Table 1).
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approach as well as 3D-CRT and dosimetric
comparison. For visualization of small bowel, all
patients were given three glasses of gastrograffin oral
contrast and placed supine with arms above their
head on a rigid foam cradle. Thirty minutes after
drinking contrast, CT scans of the abdomen and
pelvis were obtained. The AcQsim scanner (Picker,
Cleveland, OH) was used in three patients and the
General Electric (GE) light speed scanner (General
Electric, Milwaukee, WI) in eight patients. The
planning volume was scanned with 3.0-mm incre-
ments for the AcQsim and 2.5-mm increments for
the GE scanner. These CT imaging studies were
used to design our treatment plans. The GTV was
defined as the visible gross tumor volume. The
clinical tumor volume (CTV) was defined as expan-
sion of the GTV to encompass potential microscopic
spread of disease. The PTV for retroperitoneal
sarcoma ultimately included the GTV plus a 5-cm
margin in the superior and inferior dimensions and a
2-cm margin in the anterior/posterior and medial/
lateral dimensions. The GTV, CTV, liver, kidneys,
spinal cord, and small bowel were all outlined by the
attending radiation oncologist. These contours were
then sent to a 3-D treatment planning system (six
patients were planned on CAD plan with Helios and
five patients on Eclipse). Two plans were then
generated including a 3D-CRT plan using a beams-
eye view and an IMRT plan using inverse treatment
planning with a sliding window approach, eight to 11
coplanar beams, and a 0.25 0.5-cm minimum
beam resolution (Fig. 1). The PTV of both plans
was designed to receive 100% uniformity of dose
with the 95% isodose line encompassing the
CTVþ2.5cm and no more than þ110% inhomo-
geneity within the target volume. The 3D-CRT plan
was typically composed of parallel, opposed oblique
beams that employed multi-leaf blocking of portions
of the kidneys, small bowel, and liver. For both
IMRT and 3D-CRT plans, after 45Gy the treatment
margins were reduced to 2cm around the GTV in all
dimensions. Two patients did not receive a boost;
one was treated with 3D-CRT to 45Gy and dose
escalation was not possible secondary to OAR
toxicity and the other patient received re-irradiation
to 36Gy. The average volume treated was 3498cc
(1108–9040cc). Eighteen-MV photons were used for
the IMRT plans and 6-MV photons were used for the
conventional plans, as these energies corresponded
to the best dosing of these peritoneal-based tumors
(because high energy IMRT beams came in from
multiple directions, there was not a risk of superficial
underdosing). Because of MLC restrictions and field
widths larger than 15cm, it was necessary to employ
the technique of ‘beam splitting’.
8,17 The GTV and
OAR were all assigned an optimal dose, constraints,
and priority. Table 2 and Figure 2 illustrate the
various dose volume constraints that were placed.
The PTV and GTV were usually assigned a
constraint of 90% or greater while small bowel and
other OAR were assigned a priority of 80% or
greater. Isodose distributions, field arrangements,
and DVHs were calculated for both plans. The
prescription dose to the PTV was commonly 50.4 at
1.8Gy/fraction with 45Gy initially delivered to the
PTV followed by a cone-down boost to the GTV with
a 2.0-cm margin to 50.4Gy. One patient was treated
to 36Gy at 1.2Gy BID as a re-irradiation strategy
and another to 59.4Gy at 1.8Gy qd postoperatively.
CT simulation was used in each patient; three
patients were treated with a 3-D conformal plan
and the other eight received IMRT.
The acute toxicity of both 3-D CRT and IMRT
was measured using the RTOG grading criteria.
Using this scale, acute toxicity was assessed and
recorded during each week of treatment and 3 weeks
after radiation prior to surgery. Acute toxicity was
also measured up to 3 months after surgery. Chronic
treatment related toxicity was measured at each
follow-up examination. RTOG scoring was used
to measure both acute and chronic toxicities for
all patients. Eleven patients were observed until
March 2002. The median follow-up was 58 weeks.
Table 1. Clinicopathologic characteristics of 11 patients treated for retroperitoneal sarcoma
Pt.
no.
Age Sex Size (cm) Location Histology Grade Prim/Re TNM Stage Margins Organ
removal
1 34.4 Male 4.5 3.6 1.7 Inguinal Myxoid liposarcoma Low R T1b I Negative N
2 34.8 Female 10 10 8.5 Retroper. Embryonal
rhabdomyosarcoma
High P T2b III Negative Y
3 69.3 Female 14 9.3 6.8 Retroper. Liposarcoma High R T2b III Positive Y
4 76.9 Male 14.5 17.8 13.7 Pelvic Prostatic stromal
sarcoma
High P T2b III Negative Y
5 65.6 Female 9.3 6.5 5.4 Retroper. Liposarcoma Low R T2b II Positive N
6 56.0 Female 11 9 5 Retroper. Leiomyosarcoma High P T2b III Negative Y
7 52.0 Male 17 19 25 Retroper. Liposarcoma High P T2b III Positive Y
8 61.0 Male 23 13 19 Retroper. Liposarcoma High P T2b III Positive Y
9 82 Female 12 15 20 Retroper. Liposarcoma High P T2b III Negative Y
10 34 Female 4 5 6.5 Retroper. Leiomyosarcoma High P T2b III Negative N
11 71 Female 18 11 10 Retroper. Leiomyosarcoma High P T2b III Negative Y
IMRT for retroperitoneal sarcoma 139Patients were followed with clinical examinations,
chest X-ray, and CT scans of the abdomen/pelvis
every 3 months after completion of therapy for 2
years and following this, every 6 months.
Complete resection was defined as resection of all
gross disease with negative or microscopically
positive margins. Local recurrence was defined as
disease reoccurrence in the abdomen (retroperito-
neum, peritoneal cavity, or intra-abdominal lymph
nodes) while systemic recurrence was defined as
recurrent disease in the liver or outside the abdomen.
Local recurrence was calculated on the basis of time
from the date of surgery to the last follow-up
examination. The significance of the DVH data by
planning modality (3-D CRT versus IMRT) was
determined by a paired two-sided t-test.
Results
The beam’s eye view, radiation field arrangements,
and isodose comparisons between 3D-CRT and
IMRT are illustrated in Figs. 3 and 4. Tumor
IMRT
GTV
PTV
Small 
Bowel
(a)
186 205 18 231
40 59 176
(b)
Fig. 1. (a) Typical gantry angles for retroperitoneal sarcoma intensity modulated radiation therapy (IMRT); (b) intensity fluence
maps with different gantry angles.
140 M. Koshy et al.coverage, tumor dose received, and OAR toxicity are
further illustrated in comparative DVHs in Figs. 5
and 6. DVH data for all patients are summarized in
Table 3. For the same dose constraints assigned to
liver, small bowel, kidney, and PTV, IMRT resulted
in improved coverage of the PTV and reduced dose
to critical organs at risk. The difference was
statistically significant for dose received to the small
bowel and for the maximum and minimum dose
received to the tumor volume. For the prescription
dose to 50.4Gy, both the maximum and minimum
doses delivered to the PTV were significantly
increased by 6 and 22% respectively (P¼0.011,
P¼0.055) resulting in better dose distribution
within the tumor volume. In addition, tumor cover-
age as measured by the V95 (volume receiving 95%
of the dose) was improved from 95.3% with
conventional treatment to 98.6% with IMRT,
although this value did not reach statistical signifi-
cance. The mean average dose to the small bowel
decreased from 36Gy with conventional 3-D
conformal treatment to 27Gy using IMRT.
Furthermore, the mean dose to left kidney, liver,
and spinal cord were all decreased with the use of
IMRT. Although the difference in mean dose to the
left kidney, liver, and spinal cord structures was not
statistically significant due to the small sample size
and large standard deviation, the overall trend favors
IMRT. We believe it is possible to further decrease
the dose to the aforementioned critical structures
with IMRT, and this is being actively evaluated in
our department.
Fig. 2. Illustration of dose prescription data for Eclipse planning system.
Table 2. IMRT inverse treatment planning algorithm
constraint template for retroperitoneal sarcoma
Structure Volume
(%)
IMRT
constraint criteria
Planning treatment
volume (PTV)
100 Prescription dose:
45–50.4
Minimum dose: 45Gy
Priority: 90%
Gross tumor
volume (GTV)
100 Prescription dose: 50.4
Minimum dose: 45Gy
Priority: 90%
Small bowel 100 Maximum dose: 45Gy
75 Maximum dose: 48Gy
50 Maximum dose: 50Gy
25 Maximum dose: 55Gy
Priority: 80%
Kidney 100 Maximum dose: 12Gy
50 Maximum dose: 15Gy
Priority: 80%
Liver 100 Maximum dose: 30Gy
50 Maximum dose: 40Gy
Priority: 80%
IMRT for retroperitoneal sarcoma 141The bladder and rectum, although included in our
data, were only included in two patients, thereby
precluding conclusive findings. The doses received
by clinically significant volumes of small bowel, liver,
and kidney with both IMRT and 3D-CRT were also
analyzed (Table 4). The volume of small bowel
receiving>30Gy was significantly decreased from
63.5 25.2% (range 20–92%) to 43.1 20.6%
(range 20–92%) with IMRT compared with conven-
tional treatment (P¼0.043). In addition, the median
volume of small bowel that received a dose greater
than 50Gy and the dose delivered to one third of the
bowel volume was reduced with IMRT. The median
volume of small bowel that received a dose greater
than 50Gy was 8.8 12.1% with IMRT compared
to 23.5 34.4% for 3D-CRT (P¼0.073). Figure 7
illustrates the clear advantage of IMRT over
3D-CRT with respect to dose delivered to the
small bowel. The volume of left kidney that received
a dose greater than 25Gy decreased from 49 to 37%
with the use of IMRT.
For patients with recurrent disease, recurrence
varied from 3 to 6 years, and on average was 4.3
years. Eighty-two percent of tumors were high grade
Conventional
GTV
PTV
Small 
Bowel
(a)
BEV
conventional initial
(b) (c)
BEV
conventional boost
Fig. 3. (a) Three-dimensional conformal radiation therapy (3D-CRT) isodose curve of composite field arrangement; (b) beam’s
eye view (BEV) of 3D-CRT initial plan for patient no. 8; (c) BEV of 3D-CRT boost plan for patient no. 8; PTV, planning
tumor volume.
142 M. Koshy et al.histology while the remaining 18% were low grade
histology. The majority of the resected tumors were
liposarcoma and most patients presented with Stage
III disease. Only two patients did not present with
Stage III disease; one had Stage I, and one had Stage
II tumor. All 11 patients had complete excision of
gross tumor. On review of pathological specimens,
four patients had microscopic positive margins and
BEV
IMRT lnitial and boost
(b)
Fig. 4. (a) IMRT isodose curve of composite field arrangement; (b) 59  split-field BEV of patient no. 8; PTV, planning tumor
volume.
Conventional
GTV
PTV
Small 
Bowel
(a)
IMRT for retroperitoneal sarcoma 143the remaining seven patients had negative margins.
A total of eight patients required some element of
organ removal (defined as removal of the kidney,
spleen, pancreas, adrenals, or colon) with nephrec-
tomy the most common.
All patients were evaluated for toxicity using the
RTOG toxicity scale (Table 5). The most common
symptoms were nausea and vomiting and less
frequently diarrhea. Seven patients developed grade 2
nausea, three developed grade 2 diarrhea, and one
patient with primary groin involvement experienced
grade 2 skin toxicity. One patient, who had extensive
liver involvement and received 3D-CRT, developed
grade 3 liver toxicity 6 months after his radiation and
was hospitalized for management of ascites. This
patient had approximately 85% of his liver involved
with gross tumor and consequently 67% of the whole
liver received 30Gy, while 60% received 40Gy
with 3D-CRT. Currently, his ascites and hepatitis
resolved and he remains free of disease recurrence.
Other than this patient, there have been no other
delayed toxicities related to radiation. No genitouri-
nary (GU) or wound toxicities were observed and no
treatment breaks were necessary. At a median follow-
up of 58 weeks, there were no local recurrences and
only one patient developed disease progression with
distant metastasis in the liver (Table 6).
Discussion
Retroperitoneal sarcomas account for 14% of all soft
tissue sarcomas and 0.7% of all cancers diagnosed in
the United States.
18 Surgical resection has been and
remains the only curative modality for this disease.
19
Liposarcomas are the most common histological
subtypes and make up about 50% of specimens in
large series;
7,20,21 62.5% of our specimens were of
the liposarcoma subtype, in accord with this finding.
20
100
80
60
40
P
e
r
c
e
n
t
 
V
o
l
u
m
e
30.0 50.0 10.0 40.0 20.0
Dose (Gy)
left kidney
right kidney
spinal cord
liver
PTV
small bowel
60.0
DVHs from Conventional Plan
Fig. 5. Composite dose volume histogram (DVH) for 3D-CRT for patient no. 8.
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Fig. 6. Composite DVH of IMRT for patient no. 8.
144 M. Koshy et al.Historically, rates of complete surgical resectability
have varied from 38 to 65% with local recurrence
rates as high as 70–90%.
2,21–24 Resectability in this
study was 100% and may have been influenced by
the delivery of preoperative radiation therapy. The
vitality of a complete surgical resection has been
documented in several studies and remains the single
most important factor for survival.
23–26 Cody et al.i n
an evaluation of 158 patients noted a 5-year survival
of 40% after complete excision but only 3% survival
after an incomplete excision.
24 Because of the large
tumor size at presentation and intimate involvement
with adjacent organs, it is difficult to obtain resection
with negative margins. Even with complete resection,
local failure rates as high as 61–77% have been
reported.
20,21,24 Unlike extremity sarcoma, local
recurrence in retroperitoneal sarcoma is the primary
cause of mortality in patients. Distant metastatic
disease occurs in only one-third of patients and
usually the liver is the first site of distant spread.
22
Clearly, this is a disease in which improvements in
local control have the potential to significantly
impact survival.
In an attempt to increase local control, post-
operative radiation therapy has been given for retro-
peritoneal sarcomas. In a retrospective review of 198
patients, Heslin et al. noted patients who received
postoperative radiation had a significantly reduced
risk of local recurrence.
27 Local recurrence has
proven to be insidious in this disease with many
patients suffering recurrence after a 5-year disease-
free interval; long-term follow-up is critical for
evaluation of therapeutic intervention.
27
Doses of 60–70Gy have resulted in excellent local
control of soft-tissue sarcoma of the extremities;
extrapolating from this data it has been proposed that
dose escalation may have a significant impact on
local control of retroperitoneal sarcomas.
28 Tepper
et al. reported on 17 patients with retroperitoneal
sarcomas who were treated with external beam
radiation therapy alone (shrinking field technique).
In those patients who received a dose >60Gy, local
control was 83%, compared to local control of only
18% for those treated to <60Gy.
7 At Princess
Margaret Hospital, local infield failure rates tripled
for patients with retroperitoneal sarcoma who
received <35Gy compared to those who received
>35Gy.
5 Fein et al., in series of 21 patients with
retroperitoneal sarcoma, noted at 2-year follow-up a
local failure of 25% for those who received a dose
>55.2Gy and 38% for those <55.2Gy.
6
Most of the aforementioned reports involved the
use of postoperative radiotherapy. In this study, we
primarily used preoperative radiation, and believe
that this approach is optimal for several reasons. The
use of preoperative radiation may potentially reduce
the risk of tumor seeding by shrinking the tumor
and allowing for a more complete resection. With
preoperative radiation, tumor mass is easily defined
Table 3. Summary dose–volume histogram data showing
averages, ratio and P values for 11 patients with retroperitoneal
sarcoma (all values based on 50.4Gy prescription dose)
IMRT Conventional
(Gy)
Ratio (%)
(Gy)
(IMRT/
Conv)
P
value
PTV
D5 108 110 0.117
D50 103 100 0.272
MAX 116 110 0.011
MIN 62.3 40.1 0.055
MEAN 102.1 102 0.345
V95 98.6 95.3 0.312
Left kidney
D5 69.5 92.3 0.123
D50 45.1 46.8 0.472
MAX 87.1 97.8 0.224
MIN 13.25 29.8 0.190
MEAN 45.3 55.1 0.320
V95 21.5 35.6 0.272
Right kidney
D5 45.4 46.5 0.478
D50 29.1 34.9 0.395
MAX 58.8 60.7 0.468
MIN 10.2 15.6 0.367
MEAN 29. 29.2 0.496
Small bowel
D5 98.3 106.1 0.981 0.077
D50 54.45 72.1 0.858 0.162
MAX 103.7 106.8 1.05 0.304
MIN 13.2 15.8 0.842 0.395
MEAN 56.9 70.8 0.870 0.133
V95 22 35.1 0.633 0.190
Liver
D5 87.1 108.5 0.822 0.066
D50 40.1 43.5 0.950 0.449
MAX 95.7 112 0.896 0.080
MIN 3.8 10.1 0.264 0.243
MEAN 45.6 55.1 0.903 0.317
V95 8 25.8 0.250 0.158
Spinal cord
D5 61.5 86 0.697 0.046
D50 38.5 45.3 0.682 0.341
MAX 81.9 91.1 0.825 0.073
MIN 1.2 1.12 1.00 0.467
MEAN 37.3 47.2 0.409 0.188
V95 1.28 1.88 0.698 0.168
Bladder
D5 100 104 0.962 –
D50 76 101 0.752 –
MAX 102.5 104.5 0.981 0.152
MIN 55.4 49.2 1.13 –
MEAN 78.5 91.5 0.858 0.314
V95 40 54.5 0.734 0.284
Rectum
D5 74 94.5 0.783 0.390
D50 54.5 75 0.727 0.291
MAX 77.5 100 0.775 0.375
MIN 57.5 53 1.08 0.459
MEAN 66.5 64 1.04 0.473
V95 49.5 67.5 0.733 0.239
Abbreviations: D05, dose encompassing 5% of volume; D50, dose
encompassing 50% of volume; V95, volume receiving 95% of
the dose; Mean, mean dose; Max, maximum dose; Min, minimum
dose; IMRT, intensity-modulated radiation therapy; Conv,
conventional treatment.
IMRT for retroperitoneal sarcoma 145with CT/MRI and the risk of ‘tumor miss’ secondary
to mobility in the postoperative abdomen is
decreased. We do not employ IMRT for abdominal
tumors in the postoperative setting, primarily
because of lack of a precise and definable target
and the increased risk of OAR displacement once the
tumor has been removed. Treatment with radiation
in the preoperative setting is beneficial for OAR
because large retroperitoneal tumors often expand
normal tissue out of the radiation field, thereby
reducing exposure. Furthermore, extrapolating from
data for extremity soft-tissue sarcoma, the use of
preoperative radiation therapy may result in
improved local control, as has been observed in the
treatment of large extremity tumors.
28–30
Other attempts to increase local control through
dose escalation have included intraoperative
radiation with electrons (IOERT) and high-dose-
rate intraoperative radiation therapy (HDR-IORT).
The only randomized trial conducted on IORT was
done by the NCI in which 35 patients were
randomized to IORT (20Gy)þEBRT (35–40Gy)
Table 4. Analysis of DVHs for small bowel, left kidney, and liver comparing IMRT and 3D-CRT treatment plans for patients with
retroperitoneal sarcoma
IMRT (Mean SD; range) 3D-CRT (Mean SD; range) P value
% of Small bowel >30Gy 43.1 20.6 (20–92) 63.5 25.2 (20–97) 0.043
% of Small bowel >50Gy 8.8 12.1 (0–31) 23.5 34.4 (0–85) 0.073
Dose to 33% of small bowel 31.3 7.9 (2–48) 40.6 11.5 (2–54) 0.098
% of Left kidney >15Gy 50.3 43.9 (1–100) 55.1 39.3 (3–100) 0.422
% of Left kidney >25Gy 37.0 40.6 (0–97) 49.0 41.9 (0–100) 0.312
Dose to 33% of left kidney 27.0 19.0 (2–47) 28.7 18.6 (2–47) 0.442
% of liver >30Gy 33.3 26.3 (1–60) 49.6 37.5 (13–100) 0.201
% of liver >40Gy 26.8 23.1 (0–50) 46.0 38.1 (11–99) 0.158
Dose to 33% of liver 27.0 19.0 (10–48) 33.3 19.2 (11–55) 0.289
Table 5. Acute and chronic toxicity associated with IMRT for
retroperitoneal sarcoma (RTOG toxicity scale)
Skin Upper
GI
Lower
GI
Liver GU Wound
Grade 1 0 0 0 0 0 0
Grade 2 1 7 3 0 0 0
Grade 3 0 0 0 1 0 0
Grade 4 0 0 0 0 0 0
Table 6. Local control and follow-up of patients with
retroperitoneal sarcoma treated with IMRT/3D-CRT
Patient
number
F/U since
XRT
F/U since
surgery
Local
recurrence
Distant
metastases
11 4 1 7 N N
21 1 8 N N
37 4 N N
42 4 2 1 N N
52 3 2 1 N N
6 26 23 N Y (liver)
7* 14 11 N N
8* 13 12 N N
97 5 N N
10 5 4 N N
11* 6 11 N N
*Patients treated with 3D-CRT.
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Fig. 7. DVH comparison of small bowel for patient no. 8.
146 M. Koshy et al.vs. 50–55Gy with EBRT alone. At a median follow
up of 8 years, patients who received IORT did not
have a survival benefit but in-field local recurrence
significantly decreased from 80% in the EBRT alone
group to 40% in the IORT group.
31 In a recent
update of the MGH experience, Gieschen et al. noted
a trend toward improved local control and a signi-
ficant survival difference in those patients who had
IORT after preoperative external beam radiation for
retroperitoneal sarcomas.
32 Alektiar et al., who
employed HDR-IORT (12–15Gy) and postoperative
EBRT in a study of 32 patients, observed a local
control rate at 5 years of 62%.
33 It is evident that
IORT offers a clear local control advantage similar
to that seen with dose escalation of 3D-CRT.
Disadvantages of IORT include its decreased
availability and gastrointestinal (GI) and neurological
side effects. Sixty percent of patients who received
IORT in the NCI trial had neurological complica-
tions of peripheral and sensory neuropathy, and a
6–16% risk of neurological side effects has been noted
in other trials.
31–33 Gastrointestinal complications of
13–19% and fistula rates of 8–9% have also been
reported with the use of IORT.
31–33
We believe IMRT has the potential to increase
local tumor control with fewer side effects than
IORT. None of the patients treated with IMRT in
our series developed late GI, GU, or wound
toxicities associated with radiation and there were
no acute toxicities above grade 2. Just as normal
structures and organs would be shielded or displaced
at the time of IORT, strict dose constraints can be
placed with the use of IMRT, offering a similar
therapeutic ratio. IMRT allows delivery of optimal
dose to the tumor, while concurrently respecting the
tolerance of other OAR. We are encouraged by the
excellent toxicity profile and local control rate
achieved thus far with the use of IMRT for retro-
peritoneal sarcomas. Longer follow-up is needed to
confirm the benefit of IMRT in a disease that has a
high propensity for local failure.
Patients with retroperitoneal sarcomas succumb
to their disease process because of local recurrence
that persists for years. Attempts to minimize local
recurrence continue, and we think IMRT is a
clinically feasible method to employ. Escalation of
dose has a positive impact on local control for
retroperitoneal sarcomas and IMRT provides a
weapon to achieve this goal. The use of IMRT
results in enhanced tumor coverage and reduced
OAR toxicity, opening the door for dose escalation.
We are presently evaluating preoperative dose
escalation to 59.4Gy with IMRT. Based on this
study, we are encouraged by the excellent toxicity
profile and local control in patients with retro-
peritoneal sarcomas treated with IMRT. Further
investigation of the role of IMRT in multimod-
ality management of retroperitoneal sarcomas is
warranted.
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